Company Overview

Update
Founded:
2004
Headquarters:
New York, NY
IPO:
Went Public
Stock:
OTCMKTS:BCLI
Categories:
Biotechnology

BrainStorm Cell Therapeutics  is a biotechnology company developing autologous stem cell therapies for neurodegenerative diseases.

Description

Update

BrainStorm Cell Therapeutics (OTC.QB: BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

NurOwn™ , our proprietary, first-of-its-kind technology for the propagation and differentiation of autologous Mesenchymal Stem Cells (MSCs) into NeuroTrophic Factor (NTF)-secreting cells and their transplantation at or near the site of damage, offers the hope of conquering neurodegenerative diseases.

We are currently conducting a Phase IIa ALS clinical trial with NurOwn at the Hadassah University Medical Center in Jerusalem. In this safety and preliminary efficacy trial, 12 patients will receive combined intramuscular and intrathecal administration of NurOwn cells in three cohorts with increasing doses.... See More

Current Team (2)

Update

Funding Rounds (2) - $1M

Update
  • $800k

    Investors Unknown
    Dec 12, 2013 -Grant
  • $206.90k

    Investors Unknown
    Jul 27, 2012 -Seed Round

Offices/Locations (1)

Update
  • Office

    605 Third Avenue

    34th Floor

    New York, NY 10158

    USA

Images (1)

Update
  • E9b64beb865f1aa68fdbbc679c3dfe21